Literature DB >> 23932529

Increased risk of chronic liver disease in patients with schizophrenia: a population-based cohort study.

Jer-Hwa Hsu1, I-Chia Chien2, Ching-Heng Lin3, Yiing-Jenq Chou4, Pesus Chou5.   

Abstract

OBJECTIVE: To investigate the prevalence and incidence of chronic liver disease in patients with schizophrenia in Taiwan.
METHODS: We used a random sample of 661,266 subjects aged ≥ 18 from the National Health Research Institute database in the year 2000. Subjects with at least one primary diagnosis of schizophrenia (The International Classification of Diseases, Ninth Revision, Clinical Modification: 295) in 2000 were selected. Patients with a primary or secondary diagnosis of chronic liver disease (The International Classification of Diseases, Ninth Revision, Clinical Modification: 571) were also defined. We compared the prevalence and associated factors of chronic liver disease between patients with schizophrenia and the general population in 2000. We also compared the incidence of chronic liver disease in patients with schizophrenia and the general population from 2001 through 2010.
RESULTS: The prevalence of chronic liver disease in patients with schizophrenia (7.0%) was 1.27 times as high as that of the general population (6.1%) in 2000. The average annual incidence of chronic liver disease in patients with schizophrenia from 2001-2010 was also higher than that of the general population (2.9% vs 2.5%, risk ratio, 1.15; 95% confidence interval, 1.07-1.24). Younger patients with schizophrenia were found to have a much higher prevalence and incidence than those in the general population, and diabetes was a risk factor for patients with schizophrenia in developing chronic liver disease.
CONCLUSIONS: Patients with schizophrenia exhibited a significantly higher prevalence and incidence of chronic liver disease than those in the general population, and younger patients with schizophrenia have a much higher prevalence and incidence than those in the general population. Co-morbidity with diabetes was the primary risk factor for patients with schizophrenia to develop chronic liver disease.
© 2014 Published by Academy of Psychosomatic Medicine on behalf of Academy of Psychosomatic Medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23932529     DOI: 10.1016/j.psym.2013.06.001

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  12 in total

1.  Increased expression of soluble epoxide hydrolase in the brain and liver from patients with major psychiatric disorders: A role of brain - liver axis.

Authors:  Jiancheng Zhang; Yunfei Tan; Lijia Chang; Bruce D Hammock; Kenji Hashimoto
Journal:  J Affect Disord       Date:  2020-04-08       Impact factor: 4.839

2.  Altered expression of BDNF, BDNF pro-peptide and their precursor proBDNF in brain and liver tissues from psychiatric disorders: rethinking the brain-liver axis.

Authors:  B Yang; Q Ren; J-C Zhang; Q-X Chen; K Hashimoto
Journal:  Transl Psychiatry       Date:  2017-05-16       Impact factor: 6.222

3.  Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review.

Authors:  Haiyun Xu; Xiaoyin Zhuang
Journal:  Neuropsychiatr Dis Treat       Date:  2019-07-22       Impact factor: 2.570

4.  Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice.

Authors:  Hsiao-Pei Tsai; Po-Hsun Hou; Frank-Chiahung Mao; Chia-Chia Chang; Wei-Cheng Yang; Ching-Feng Wu; Huei-Jyuan Liao; Tzu-Chun Lin; Lan-Szu Chou; Li-Wei Hsiao; Geng-Ruei Chang
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923

5.  Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives.

Authors:  Evgeny A Ermakov; Mark M Melamud; Valentina N Buneva; Svetlana A Ivanova
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

6.  Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice.

Authors:  Geng-Ruei Chang; Po-Hsun Hou; Wei-Cheng Yang; Chao-Min Wang; Pei-Shan Fan; Huei-Jyuan Liao; To-Pang Chen
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-16

7.  Clozapine Worsens Glucose Intolerance, Nonalcoholic Fatty Liver Disease, Kidney Damage, and Retinal Injury and Increases Renal Reactive Oxygen Species Production and Chromium Loss in Obese Mice.

Authors:  Geng-Ruei Chang; Hsien-Yueh Liu; Wei-Cheng Yang; Chao-Min Wang; Ching-Fen Wu; Jen-Wei Lin; Wei-Li Lin; Yu-Chen Wang; Tzu-Chun Lin; Huei-Jyuan Liao; Po-Hsun Hou; Chee-Hong Chan; Chuen-Fu Lin
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

8.  Association of Prenatal Famine Exposure With Inflammatory Markers and Its Impact on Adulthood Liver Function Across Consecutive Generations.

Authors:  Shiwei Yan; Jingqi Ruan; Yu Wang; Jiaxu Xu; Changhao Sun; Yucun Niu
Journal:  Front Nutr       Date:  2022-01-03

9.  Psychiatric Comorbidities and Liver Injury Are Associated With Unbalanced Plasma Bile Acid Profile During Methamphetamine Withdrawal.

Authors:  Yuru Ma; Hongjin Wu; Huawei Wang; Fengrong Chen; Zhenrong Xie; Zunyue Zhang; Qingyan Peng; Jiqing Yang; Yong Zhou; Cheng Chen; Minghui Chen; Yongjin Zhang; Juehua Yu; Kunhua Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-03       Impact factor: 5.555

10.  Hepatitis C-associated late-onset schizophrenia: a nationwide, population-based cohort study.

Authors:  Jur-Shan Cheng; Jing-Hong Hu; Ming-Yu Chang; Ming-Shyan Lin; Hsin-Ping Ku; Rong-Nan Chien; Ming-Ling Chang
Journal:  J Psychiatry Neurosci       Date:  2021-11-02       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.